Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisi
Search jobs 08-Apr-2021 Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer -Preliminary data from 103 patients in the expansion portion of a Phase 1b clinical trial demonstrated the drug was well tolerated and anti-tumor activity was noted - Unique opportunity to leverage CELsignia platform to advance development of a first-in-class targeted therapy - Management to host conference call/webcast today, April 8, 2021, at 5:00 p.m. ET MINNEAPOLIS...
Source: pharmiweb.com